文献速递区域麻醉与超声心胸血管麻醉

硬膜外麻醉镇痛与肺癌术后无复发生存的随机试验

Epidural Anesthesia-Analgesia and Recurrence-free Survival after Lung Cancer Surgery: A Randomized Trial.
PubMed 文献 · Anesthesiology · 2021-01-01

本研究纳入400例拟行胸腔镜肺癌切除术的成人,随机分为全麻联合术中硬膜外麻醉及术后硬膜外镇痛组或全麻联合静脉阿片镇痛组。主要结局无复发生存两组相似(调整HR 0.90,95%CI 0.60-1.35,P=0.608),总生存和癌症特异性生存亦无显著差异,但硬膜外组术中低血压发生率更高。

要点

  • 硬膜外麻醉镇痛未改善肺癌术后无复发生存。
  • 硬膜外组术中低血压发生率显著增高(61% vs 47%)。
  • 总生存和癌症特异性生存两组无显著差异。

核心结论

  • 与单纯全麻相比,硬膜外麻醉镇痛未改善肺癌根治术后的无复发生存、总生存或癌症特异性生存。

研究设计与样本

  • 随机对照试验,纳入400例拟行胸腔镜肺癌切除术的成人,1:1随机分为全麻联合静脉阿片镇痛组(n=200)或全麻联合硬膜外麻醉及镇痛组(n=200)。

主要发现

  • 无复发生存事件:单纯全麻组54例(27%),联合硬膜外组48例(24%),调整HR 0.90(95%CI 0.60-1.35,P=0.608)。
  • 总生存事件:单纯全麻组25例(13%),联合硬膜外组31例(16%),调整HR 1.12(95%CI 0.64-1.96,P=0.697)。
  • 癌症特异性生存事件:单纯全麻组24例(12%),联合硬膜外组29例(15%),调整HR 1.08(95%CI 0.61-1.91,P=0.802)。
  • 术中低血压:联合硬膜外组121例(61%),单纯全麻组94例(47%),相对风险1.29(95%CI 1.07-1.55,P=0.007)。

临床怎么用

  • 对于肺癌手术患者,不应基于改善肿瘤学结局的目的常规选择硬膜外麻醉镇痛。
  • 选择硬膜外麻醉镇痛时需注意术中低血压风险增加。

局限性

  • 随访中位时间32个月(四分位距24-48),置信区间包含显著获益和显著 harm,不能排除临床重要差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Regional anesthesia and analgesia reduce the stress response to surgery and decrease the need for volatile anesthesia and opioids, thereby preserving cancer-specific immune defenses. This study therefore tested the primary hypothesis that combining epidural anesthesia-analgesia with general anesthesia improves recurrence-free survival after lung cancer surgery. METHODS: Adults scheduled for video-assisted thoracoscopic lung cancer resections were randomized 1:1 to general anesthesia and intravenous opioid analgesia or combined epidural-general anesthesia and epidural analgesia. The primary outcome was recurrence-free survival (time from surgery to the earliest date of recurrence/metastasis or all-cause death). Secondary outcomes included overall survival (time from surgery to all-cause death) and cancer-specific survival (time from surgery to cancer-specific death). Long-term outcome assessors were blinded to treatment. RESULTS: Between May 2015 and November 2017, 400 patients were enrolled and randomized to general anesthesia alone (n = 200) or combined epidural-general anesthesia (n = 200). All were included in the analysis. The median follow-up duration was 32 months (interquartile range, 24 to 48). Recurrence-free survival was similar in each group, with 54 events (27%) with general anesthesia alone versus 48 events (24%) with combined epidural-general anesthesia (adjusted hazard ratio, 0.90; 95% CI, 0.60 to 1.35; P = 0.608). Overall survival was also similar with 25 events (13%) versus 31 (16%; adjusted hazard ratio, 1.12; 95% CI, 0.64 to 1.96; P = 0.697). There was also no significant difference in cancer-specific survival with 24 events (12%) versus 29 (15%; adjusted hazard ratio, 1.08; 95% CI, 0.61 to 1.91; P = 0.802). Patients assigned to combined epidural-general had more intraoperative hypotension: 94 patients (47%) versus 121 (61%; relative risk, 1.29; 95% CI, 1.07 to 1.55; P = 0.007). CONCLUSIONS: Epidural anesthesia-analgesia for major lung cancer surgery did not improve recurrence-free, overall, or cancer-specific survival compared with general anesthesia alone, although the CI included both substantial benefit and harm.

来源:Anesthesiology,查看原文。版权归原作者所有。

引用

  1. Xu ZZ, Li HJ, Li MH, et al. Epidural Anesthesia-Analgesia and Recurrence-free Survival after Lung Cancer Surgery: A Randomized Trial. Anesthesiology. 2021. PMID: 34192298. doi:10.1097/ALN.0000000000003873

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。